Artificial Intelligence

With a hot obesity pipeline and a key neurology asset, Nxera Pharma's J.P. Morgan talk is a crucial test of its plan for global leadership.

William Healey, a 25-year veteran, takes the helm as IAAO's 2026 President, guiding the future of global property valuation amid technological change.

With a $257M war chest and a veteran team, BlossomHill will showcase its innovative pipeline for lung cancer and leukemia at the pivotal JPM conference.

With surging revenue for its cholesterol drugs and new guideline backing, Esperion outlines its strategy for profitability and pipeline expansion.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

Post-merger, Kepler Fusion unveils its strategy for commercializing compact, aneutronic fusion reactors, betting on a distributed 'Power-as-a-Service' model.

At CES 2026, a new platform combines Dolby Atmos FlexConnect and UWB tech, promising to make high-end surround sound easier than ever before.

A new partnership aims to accelerate driver safety tech in next-gen vehicles, merging AI monitoring with a fortress-like operating system.

With 35 years at the company, new CEO John Baylouny plans to accelerate R&D and expand into new markets, building on a period of strong growth.

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

Routeware appoints proven tech leaders Jeremy Collins and Ray Greer to drive its next growth phase, focusing on platform modernization and market leadership.

With blockbuster sales from VYJUVEK, Krystal Biotech heads to J.P. Morgan with investors eager for news on its global growth and ambitious pipeline.

A tiny implant stimulating the vagus nerve offers new hope for severe RA. A landmark study now validates this bioelectric therapy for patients out of options.

Off The Hook's new luxury division leverages AI and an integrated model to secure ~$100M in listings and close 22 deals in its explosive first quarter.

A new integration brings Ceres AI's insights directly into the John Deere Operations Center, tackling data fragmentation for growers and insurers alike.

A new therapy claims to reverse cellular aging to cure disease, but its patient-funded trial model sparks a debate on equity and medical ethics.

Amid a capacity crisis, a new model blending AI with human oversight gains traction, promising efficiency without sacrificing the crucial element of patient care.

China's ETF market had a record 2025, fueled by AI breakthroughs and state support. A look at the boom, the leaders, and the risks ahead.

Circle Pharma will unveil its pipeline of novel oral macrocycle drugs targeting elusive cancer drivers at the influential J.P. Morgan Healthcare Conference.

With record Q3 earnings and strong analyst ratings, Red Violet is set to present its identity intelligence growth strategy at the prestigious Needham conference.